key: cord-0729310-cbonl90y
authors: Redecke, Vanessa; Tawaratsumida, Kazuki; Larragoite, Erin T.; Williams, Elizabeth S.C.P.; Planelles, Vicente; Spivak, Adam M.; Hirayama, Lincoln; Elgort, Marc; Swenson, Shane; Smith, Rick; Worthen, Bryan; Zimmerman, Russ; Slev, Patricia; Cahoon, Ben; Astill, Mark; Häcker, Hans
title: A rapid and affordable point-of-care test for detection of SARS-CoV-2-specific antibodies based on hemagglutination and Artificial Intelligence-based image interpretation
date: 2021-07-20
journal: Res Sq
DOI: 10.21203/rs.3.rs-712902/v1
sha: f72dcf87266a76d3016ca505cae271cde1b6710a
doc_id: 729310
cord_uid: cbonl90y

Diagnostic tests that detect antibodies (AB) against SARS-CoV-2 for evaluation of seroprevalence and guidance of health care measures are important tools for managing the COVID-19 pandemic. Current tests have certain limitations with regard to turnaround time, costs and availability, particularly in point-of-care (POC) settings. We established a hemagglutination-based AB test (HAT) that is based on bi-specific proteins which contain a dromedary-derived antibody (nanobody) binding red blood cells (RBD) and a SARS-CoV-2-derived antigen, such as the receptor-binding domain of the Spike protein (Spike-RBD). While the nanobody mediates swift binding to RBC, the antigen moiety directs instantaneous, visually apparent hemagglutination in the presence of SARS-CoV-2-specific AB generated in COVID-19 patients or vaccinated individuals. Method comparison studies with assays cleared by emergency use authorization (EUA) demonstrate high specificity and sensitivity. To further increase objectivity of test interpretation, we developed an image analysis tool based on digital image acquisition (via a cell phone) and a machine learning algorithm based on defined sample-training and –validation datasets. Preliminary data, including a small clinical study, provides proof of principle for test performance in a POC setting. Together, the data support the interpretation that this AB test format, which we refer to as ‘NanoSpot.ai’, is suitable for POC testing, can be manufactured at very low costs and, based on its generic mode of action, can likely be adapted to a variety of other pathogens.

The COVID-19 pandemic caused by SARS-CoV-2 passed its first anniversary with more than 2.5 million deaths worldwide. While initial countermeasures were largely restricted to therapeutic interventions for those with severe infections and prophylactic social distancing, recent clinical studies demonstrated efficacy for various SARS-CoV-2 vaccines, whose deployment is underway in many countries. Still, proper pandemic management hinges on the availability of diagnostic tests, including those revealing the presence of antibodies (AB) against the virus.

On a population scale, results obtained by these tests reveal seroprevalence and the dynamics of virus spread, helping to predict susceptibility of a population and guiding health care decisions. On an individual level, such test results indicate previous SARS-CoV-2 infection or successful vaccination and have likely high predictive value for disease susceptibility. While numerous AB tests are available, they do have certain limitations. Tests performed in reference laboratories, such as enzyme-linked immunosorbent assays (ELISA) and related technologies, require special equipment, are relatively expensive and typically associated with long turn-around times from sample acquisition to results. Point-of-care (POC) tests, like the lateral flow immuno-assay (LFIA or LFA), can be conducted with minimal laboratory equipment, but typically show reduced sensitivity compared to tests conducted in reference labs and are also relatively expensive 1 2 3 . Moreover, analysis is performed by visual inspection, which is subjective in nature and thus affects specificity and sensitivity dependent on more or less conservative interpretation 4 . An alternative format for detection of antigen-specific antibodies in whole blood are hemagglutination tests (HAT). This format is typically based on bi-specific proteins with one moiety, e.g. an AB, binding to red blood cells (RBC) and the other moiety encompassing the antigen, e.g. a virus protein as target for the investigated AB. Antigen-specific AB contained in whole blood bind to the test antigen and mediate visible agglutination of RBC within seconds to minutes (Fig. 1a) 5 . Tests based on such fusion proteins were validated in comparison to a number of FDA-approved assays including ELISA, Western blotting and immunofluorescence assays (IFA), demonstrating remarkably comparable performance 5 6 . A more recent development of this principle employed as RBC-binding moiety a dromedary-derived single variable domain on a heavy chain (VHH)(nanobody) against Glycophorin A (GPA), which is expressed at high levels on RBC 7 . In a proof of principle assay, an E. coli-expressed fusion protein of this nanobody (IH4) and HIV p24 demonstrated high affinity binding of GPA (KD = 33.72 nM) and the detection of p24-directed AB in the plasma of an HIV-positive patient 7 . Here, we describe the development of a test, which is based on the latter approach using a modified form of the nanobody targeting GPA and two antigens of SARS-CoV-2, i.e. the Spike-RBD and the Nucleocapsid protein.

Analyses related to protein production, RBC-binding and hemagglutination in the presence of SARS-CoV-2specific antibodies suggest excellent test performance. Moreover, artificial intelligence (AI)-based analysis of digital images obtained via cell phone suggest that test interpretation can be objectified and quantified by computer analysis. Given the simplicity, robustness and low production costs, this test may facilitate the assessment of AB responses against SARS-CoV-2 in POC settings, including those with limited resources, and thus contribute to pandemic management.

We chose the GPA-directed nanobody IH4 as starting point due to the known robustness of nanobodies and the availability of sequence information 7 . Two mutations were introduced to enable efficient protein secretion in mammalian cells (see Methods). As illustrated in Fig. 1b , we fused the IH4 nanobody to two viral antigens, i.e. the receptor-binding domain of the Spike protein (Spike-RBD) of SARS-CoV-2 (NanoSpike) and the Nucleocapsid (NanoNuc). 2xαSpike-Nano, tandem-fusion construct of two Spike-RBD-binding H11-D4 nanobodies, separated by flexible linker; Hinge-IgG1-FC, dimerizing Hinge-FC moiety of IgG1. (c) SyproRuby-stained SDS PAGE of 3 µg of indicated proteins that were expressed in Expi293F cells and purified by one-step affinity purification. Protein yield from 25 ml of Expi293F-cell cultures were 2 mg (NanoControl), 3.75 mg (NanoSpike), 0.55 mg (NanoNuc) and 1.25 mg (NanoLink). Defined amounts of BSA are shown for comparison. The Spike-RBD was shown to represent a highly immunogenic region in various analyses 8 9 10 . Antibodies against the Spike-RBD were found to correlate well with neutralizing activity against the virus in both adults and children 11 12 13 . Last, the majority of currently available vaccines are based on the Spike protein; as such, tests incorporating this protein will allow assessment of successful vaccination. AB against the Nucleocapsid are also found in the majority of SARS-CoV-2-infected individuals, and AB titers are particularly high in severe cases 11 .

Since most vaccines are based on the Spike protein, Nucleocapsid-directed AB can be used to identify AB obtained during natural infection. Of note, neither antigen appears to cross-react with AB against SARS-CoV or seasonal CoV infections, providing the required predictive value to identify AB against SARS-CoV-2 14 . In contrast to the original approach using E. coli as expression host, we focused on mammalian protein expression.

Spike protein is physiologically targeted to the secretory pathway, which is likely required for proper protein folding and accompanied by glycosylation, which in turn may be relevant for the AB response and test specificity 15 . Thus, to allow for proper targeting to the secretory pathway, we added a secretion signal derived from Interferon-beta to the N-terminus of the fusion protein (Fig. 1b) . The Nucleocapsid protein does not contain a secretion signal and is expressed primarily in the cytoplasm. However, initial expression studies suggested increased protein yield and purity when expressed as soluble protein. We therefore followed a similar strategy as used for the NanoSpike and added a secretion signal to the N-terminus (Fig. 1b) . A tandem Strep-tag was fused to the C-terminus to allow for efficient one-step protein purification. Flexible glycine-serine-containing linkers were placed between the functional units of the fusion protein to avoid interference of the different domains. A similar protein lacking a viral antigen was cloned as negative control (NanoControl, Fig. 1b) . Last, we designed a positive control protein. Here we took advantage of a recently published nanobody against the Spike-RBD, H11-D4 16 . This nanobody was arranged in tandem to increase affinity and linked to the Hinge-FCdomain of IgG1, which forms constitutive dimers. Based on these characteristics, we would expect this protein (NanoLink) to act as surrogate for physiological AB directed against the Spike-RBD and, in the presence of NanoSpike, induce hemagglutination. We expressed these proteins first in small scale, then in larger scale experiments in Expi293F cells (Invitrogen), which are optimized for high-density growth in suspension. Protein expression and Strep-tag-based affinity purification were efficient, resulting in virtually homogenous protein preparations with robust yields (Fig. 1c ). NanoNuc and, to some extent NanoLink, showed a number of slower migrating bands indicating glycosylation.

We first confirmed binding of recombinant proteins to human RBC by flow cytometry (Fig. 2a) . A kinetics analysis illustrates the rapid and quantitative process involved (Fig. 2b) . We next tested if AB-mediated cross-linking of NanoSpike triggers hemagglutination. As shown in Fig. 3a , a αStrep-tag AB induced almost instant, clearly visible hemagglutination in the presence of NanoControl or NanoSpike. Neither protein showed any agglutinating activity on its own. Given that NanoControl binds RBC, but lacks a viral antigen, this protein controls efficiently for non-specific (antigen-independent) cross-linking activity. We note that the αStrep AB is a monoclonal IgG1 AB, suggesting that the valency of IgG is sufficient to trigger agglutination.

To simplify the interpretation of the agglutination test, we utilized the positive control protein (NanoLink) as depicted in Fig. 1b . Given its Spike-RBD-binding nanobody (H11-D4) and dimerizing IgG1 FC-domain, this protein is expected to mimic the function of physiological AB directed against the Spike protein and, as a consequence, to induce hemagglutination in the presence of NanoSpike. As shown in Fig. 3b , this is indeed the case. assay of whole EDTA blood that was treated with NanoControl or NanoSpike protein (30 µg/ml) in the presence or absence of AB against the Strep-tag. (b) Hemagglutination assay of blood that was treated with NanoSpike (30 µg/ml) in the absence or presence of NanoLink at concentrations corresponding to a molar ratio of NanoSpike-to-NanoLink of 9:1, 3:1 and 1:1. Blood treated with NanoLink, NanoControl, NanoSpike or a combination of NanoSpike and αStrep AB is shown for comparison. Time points indicate the duration of agglutination. (c, d) Hemagglutination assay of blood from a convalescent COVID-19 patient that was treated with indicated concentrations of NanoSpike (c) or NanoNuc (d). Samples treated with NanoControl (30 µg/ml) or NanoSpike (30 µg/ml) plus NanoLink (14.3 µg/ml) serve as controls. Time points indicate the duration of agglutination. (e) Phase contrast microscopy of blood from a convalescent COVID-19-patient that was incubated with NanoControl and NanoSpike. (f) Phase contrast microscopy of blood from a convalescent COVID-19-patient and a COVID-19-negative control patient, which was incubated with NanoSpike.

Up to a molar ratio of 9 to 1 of NanoSpike vs. NanoLink, NanoLink was inducing clearly visible hemagglutination, while NanoLink alone remained without effect. As such, NanoLink and NanoControl recapitulate the appearance of a negative and positive test results, facilitating visual interpretation. Having established negative and positive controls, we used blood from a convalescent COVID-19 patient to test if NanoSpike and NanoNuc trigger hemagglutination in the presence of SARS-CoV-2-specific antibodies. For this purpose we titrated the recombinant proteins to establish robust conditions. In a range of 3 -30 µg/ml, both, NanoSpike and NanoNuc, triggered hemagglutination, which became visible almost instantly and was fully developed between 1 to 3 min ( Fig. 3c,d) . Concentrations of recombinant protein above 30 µg/ml reduced agglutination in case of Nanospike, while concentrations below 3 µg/ml were less active in case of both, NanoSpike and NanoNuc. Proteins at 3 µg/ml were active, but induced slightly delayed agglutination in comparison to proteins at 10 and 30 µg/ml (Fig.   3c ,d). Neither NanoSpike nor NanoNuc induced hemagglutination at any concentration in the blood of a healthy donor (Supplementary Figure 1 ).

Based on these results, we continued our studies with proteins at 30 µg/ml. As expected, macroscopic hemagglutination was reflected by microscopically apparent formation of RBC-clusters induced by NanoSpike in the blood of a convalescent COVID-19-patient (Fig. 3e) . NanoControl did not induce any visible cluster formation in the same blood. Likewise, NanoSpike failed to induce RBC-cluster formation in the blood of a COVID-19-negative control patient (Fig. 3f) .

Activity of the proteins was maintained for extended periods of time (up to 16 weeks) when stored in a refrigerator at 4°C (Supplementary Figure 2 ). Storage at room temperature (25°C) and at 37°C did also not show a loss in activity when assessed with undiluted serum; five-fold dilution of the serum indicated a slight reduction in activity, suggesting that storage at 4°C (or subzero temperatures in a freezer) will be advantageous if the proteins are stored for extended period of times. We note that optimization of storage buffers is expected to further improve this aspect.

Given that blood serum can be stored for extended periods of time and is thus more easily available, we tested if serum from a convalescent COVID-19-patient triggered NanoSpike-/ NanoNuc-mediated hemagglutination when mixed with washed RBC from a COVID-19-negative healthy subject. As expected, both serum and whole blood containing SARS-CoV-2-specific AB induced very similar hemagglutination (Fig. 4a) .

Interestingly, spotting and drying of the proteins on the test-cardboard resulted in a hemagglutination reaction that was very similar to application of the proteins in soluble form (Fig. 4b) . Given its practical simplicity, this format may be particularly suitable as POC test. Still, experiments employing specialist lab equipment for protein spotting and longitudinal evaluation of protein activity will be required to substantiate this possibility.

Taken together, RBC-targeting nanobody constructs containing SARS-CoV-2-derived antigens bind swiftly and quantitatively to RBC and induce hemagglutination in the presence of virus-specific antibodies. Protein stability is appropriate for a POC environment, and preliminary analyses using cardboard (polypropylene)-immobilized protein suggest feasibility. Given the nature of the proteins used and the visual test appearance, we refer to this test as NanoSpot.

(a) Hemagglutination assay based on samples from a convalescent COVID-19-patient that was treated with indicated proteins. Whole EDTA blood was used directly (left) or serum was isolated and mixed at a physiological ratio with washed RBC from a COVID-19-negative blood group 0 subject (right). (b) Hemagglutination assay based on convalescent serum (at indicated dilutions) and recombinant proteins that were either spotted on cardboard (made from 100% extruded polypropylene) and stored at RT overnight (left), or used in their soluble form as described in previous experiments (right). The same cardboard and the same amount of recombinant proteins was used for both conditions.

Based on these results, we proceeded to evaluate the test performance of NanoSpot, using a larger number of de-identified samples (serum) from individuals, which had been evaluated at ARUP (Associated Regional and University Pathologists, Inc.) using tests that had received EUA from the FDA for the detection of Spike-and Nucleocapsid-specific antibodies, i.e. an ELISA (EUROIMMUN) and a chemiluminescent immunoassay (CIA)(Abbott), respectively. Hemagglutination was observed for up to three minutes. Using a total of 82 samples, NanoSpike-and ELISA-based tests agreed to 98% for both COVID-19-positive and -negative samples, indicating comparable specificity and sensitivity (Table 1) . Using 80 and 108 samples that were CIA-positive and -negative, respectively, NanoNuc showed a negative agreement of 98% and a positive agreement of 74%, indicating high specificity, but reduced sensitivity in comparison to the Nucleocapsid CIA and, likely, NanoSpike.

Thus, we focused primarily on NanoSpike for further development. Together, NanoSpike appears to perform comparable to the EUROIMMUN ELISA, while NanoNuc appears overall less sensitive than reference lab tests. Table 1 Comparative analysis of NanoSpike-and NanoNuc-mediated hemagglutination tests.

Hemagglutination assays based on serum from COVID-19 convalescent and control patients was performed using NanoSpike and NanoNuc and directly compared to results obtained from the Nucleocapsid CIA (Abbot)

and Spike ELISA (EUROIMMUN), respectively. Hemagglutination assay controls, i.e. NanoControl and NanoLink were included to aid visual test interpretation.

A critical aspect in pandemic management, both from an epidemiological and analytical perspective, is the emergence of novel virus strains with altered characteristics related to transmission, pathogenicity and immunogenicity. Ideally, analytical test formats should entail the flexibility for swift adaptation to such new variants and their changed molecular characteristics. Taking advantage of the simplicity of establishing new protein variants for the NanoSpot assay, we tested this aspect formally by introducing one of the emerging mutations into the Spike-RBD of NanoSpike, i.e. N501Y, which was first identified in a variant of the United Kingdom (B1.1.7). Protein production was comparably efficient to the wildtype (wt) protein (Fig. 5a) . Using a wide range of concentrations of convalescent serum, we found that NanoSpike-mediated hemagglutination was comparably efficient between wt and the N501Y mutant protein (Fig. 5b) . While this observation is consistent with recent reports demonstrating that human convalescent sera efficiently neutralize viruses with N501Y

substitutions, the data also demonstrate that the NanoSpot assay can swiftly be adapted to mutations in the virus genome and possible changes in antigenicity 17 18 19 . were used to reveal potential differences in agglutination activity.

Similar to lateral flow assays, agglutination tests are typically interpreted by visual inspection. Even with the help of the negative and positive controls in the NanoSpot assay, interpretation based on human visual inspection remains subjective and can be affected by the training and expertise of the individual interpreting the test. We thus asked if a more objective method could be developed, and specifically, if an image-based deep-learning algorithm could be trained to identify and interpret hemagglutination on card boards. In its ultimate configuration we envision a scenario where (i) a cell phone app directs the acquisition of the agglutination-test image, (ii) the image is immediately uploaded to a server for analysis and interpretation by AI and (iii) the AI diagnosis is quickly returned to the cell phone user (see below).

We initially developed a machine-learning algorithm to detect and classify agglutinated and non-agglutinated Table 2 , visual and AI-based test interpretation in the holdout set showed perfect correlation. All visually positive and negative samples were classified correctly by AI. As such, an image-based, AI-driven approach can be used, in principle, to identify hemagglutination on cardboards with high confidence. Figure 3) . AI-based interpretation using the algorithm described above will identify such control samples as agglutination-positive with the consequence to invalidate such tests. Given these considerations and the fact that the level of agglutination correlates with AB titers (see below), we hypothesized that AI could be trained to quantify agglutination and, possibly, AB titers. This seemed particularly feasible as samples with negative (or minimal) and positive (or maximum) agglutination are integrated into the test procedure as controls, providing a possible scale for relative quantification.

In a first attempt towards this quantitative goal, we focused on a step-wise quantification model where a total of 2591 samples were assigned visually to 10 arbitrary bins according to agglutination levels (Fig. 6a) , implemented as a generalization from the two original labels, "Agglutination negative" and "Agglutination positive" to 10 new labels: "Agglutination 0" (no agglutination) through "Agglutination 9" (maximum agglutination)(Supplementary Table 1 ). The samples were then divided into 2326 training and 265 validation labels, followed by training of a deep learning object detection model to identify the location, type (i.e., Agglutination 0-9), and confidence for each blood spot in a manner similar to the previous binary classifier. After training, the model was tested on a holdout set containing 237 samples that had not been used for training. As shown in Fig. 6b , the AI-based method assigned all samples to the same bin or at most one bin apart from those picked by human visual inspection.

This is particularly remarkable as agglutination is continuous in nature and assignment of samples to discrete bins by visual inspection was subjective. On the expanded holdout test set, the maximum spurious prediction confidence was 0.41, and the minimum true positive blood spot prediction confidence was 0.53. Thus, for subsequent processing, predictions below a confidence threshold of 0.5 were considered spurious. 2-fold (c-e) and 1.5-fold (f) dilution steps were used as indicated.

In order to characterize directly the relationship between AB titer and level of agglutination (as assigned through AI), we titrated serum from COVID-19 patients, followed by AI-based image interpretation. The EUROIMMUN ELISA was used for comparison. Using two-fold dilution steps, both NanoSpot and ELISA showed a clear, comparable relationship between AB titer and AI-bins (NanoSpot.ai), respectively arbitrary units (ELISA) (Fig. 6ce ). More refined serum titration at 1.5-fold dilution steps showed an approximately linear relationship of AB titer and AI-bins over an 8-fold dilution range, with a two-fold dilution corresponding to a distance of ~2 AI-bins (Fig.   6f ). Together, the data suggest that an image acquisition and AI-based interpretation method can be used to identify hemagglutination. Given the relationship between AB titer and level of agglutination, the data also suggest that this method can be used to provide a semi-quantitative assessment of AB titers. Provided the combination of NanoSpot and AI, we refer to this approach as NanoSpot.ai.

As noted, our ultimate vision for this test is a scenario where a cell phone app directs the acquisition of the agglutination-test image, that image is uploaded to a server for analysis and interpretation by AI, and the AI diagnosis is returned to the cell phone user. To this end we established testing cards made out of cardboard containing two regions for QR-code stickers for sample identification and camera focusing. We also established an iOS-based mobile app, which initiates a timer upon recognition of the QR-codes (at the start of the agglutination reaction) and captures an image after a selected time frame (to allow for agglutination). The captured image is immediately uploaded via the internet to a computer server at Techcyte for analysis. The complete setup is shown in Supplementary Movie 1.

Using this pipeline and to validate NanoSpot.ai in a real-world setting, we performed a small clinical study enrolling four groups of patients: (1) patients who had neither been infected by SARS-CoV2 nor had been vaccinated (n=15), (2) patients who had not been infected, but had been vaccinated (n=17), (3) patients who had been infected in the past (self-declared positive PCR result), but had not been vaccinated (n=15) and (4) patients who had been infected (self-declared positive PCR result) and had been vaccinated (n=10). Patient blood for NanoSpot.ai was obtained by finger-stick. In parallel, venous blood samples were obtained for EUAapproved tests, i.e. a Spike-ELISA (EUROIMMUN), a Spike-CIA (Siemens) and a Nucleocapsid-CIA (Abbot). In addition, to substantiate interpretation of discrepant results, we conducted the so-called S-Flow assay 20 . This flow cytometry-based assay requires a dedicated lab environment and significant effort; however, it detects

Spike-specific antibodies with high specificity and sensitivity 20 .

The complete set of the results is provided in Supplementary Table 2 . All patient samples were analyzed successfully by all methods with the exception of three samples where image quality obtained by NanoSpot.ai was insufficient or the confidence score was below the set threshold, invalidating the test (NANO_3, _39, _44;

Supplementary Figure 4 ). We envision that such cases will trigger re-testing once the mobile app is fully developed and that their incidence will be reduced by more extensive AI training and app improvement.

NanoSpot.ai tests were ranked positive if analyte and positive controls were two or more bins above negative control, were ranked equivocal if analyte was only one bin above negative control, and were ranked negative if analyte was in same bin or below the negative control. Table 2 and Supplementary Fig. 5 ). All of those samples were close to the detection limit in the ELISA (Supplementary Table. 2). As a result, the negative percent agreement (NPA) of the Spike-CIA and both NanoSpot.ai and ELISA was reduced (Table 3) . One sample identified as (low) positive in the ELISA (NANO_54) was ranked equivocal in the NanoSpot.ai assay (due to a low positive control), while one sample identified as positive in the NanoSpot.ai assay was ranked negative in the ELISA (NANO_48). The latter sample scored positive in the Nucleocapsid-CIA and S-Flow assay, suggesting correct assessment by NanoSpot.ai (Supplementary Figure 5) . Two ELISA-equivocal samples were also ranked equivocal by NanoSpot.ai, while one ELISA-equivocal sample (NANO_13) was ranked positive by NanoSpot.ai. This sample scored clearly positive in the S-Flow assay, suggesting correct assessment by NanoSpot.ai (Supplementary Figure 5) . As such, while the Spike-CIA appears to be slightly less sensitive in this limited set of patients, ELISA and NanoSpot.ai show very similar performance and overall excellent agreement, particularly when considering the challenging set of low-titer samples (Table 3) . This agreement is also apparent in the correlation of signal intensities between the two tests, reflected by a Pearson correlation coefficient of Figure 6) , further supporting the conclusion that NanoSpot.ai can provide a semiquantitative assessment of AB titers similar to other test formats. Taken together, this relatively small clinical study indicates that NanoSpot.ai performs with regard to specificity and sensitivity comparably to established EUA-approved AB tests. The data also suggest that a semi-quantitative AB analysis based on the NanoSpot.ai platform is possible.

The data in this paper show that a hemagglutination test based on bispecific proteins can be used to detect SARS-CoV2-specific AB in finger-stick blood. The simple format, inexpensive reagents and fast results suggest particular suitability as POC test. The data further suggest that AI-driven image analysis can be used to identify and quantify hemagglutination on synthetic planar surfaces to determine relative AB titers. While the current App supports uploading and image interpretation, we envision that future versions will return the test result immediately to the cell phone user. The simple modification of test reagents allows quick adaptation to emerging mutant virus strains, providing the flexibility needed to respond to the evolving pandemic.

For the assay described in this paper, two principal modes of test readout are possible, i.e., visual inspection and image/AI-based test analysis. Both take advantage of controls, which provide direct comparatives. While those may be less important for strong agglutination reactions, e.g., upon vaccination, the negative control is critical to differentiate weak positive reactions from subtle, spontaneous agglutination found in some patients.

The human eye is highly capable to identify such differences, making correct diagnoses very likely. Still, visual image interpretation is subjective in nature and can thus lead to incoherent test interpretation amongst different investigators. This problem is well recognized in other test formats, such as classic LFAs, which typically rely on visual interpretation 21 22 . To address this issue, we used a deep-learning algorithm to train an AI model on images of agglutination spots obtained by cell phone. In a first attempt, we trained the model only on blood spots with and without apparent agglutination. This attempt was very successful, allowing AI-based identification of hemagglutination with high confidence. However, this plus/minus interpretation did not allow differentiation of mentioned cases of spontaneous agglutination (necessitating invalidation of some tests) and also did not allow for quantification of AB titers. The latter seemed attractive due to the direct correlation of AB-titer and 'level' of agglutination. In a proof-of-concept application, we generated 10 bins representing arbitrary levels of increasing agglutination to generate a discontinuous standard curve ranging from non-detectable to maximal agglutination.

Training the model on these bins resulted in a remarkable correlation between visual and AI-based image interpretation, ultimately achieving a test performance in a small clinical study that was comparable to standard EUA-approved tests. Importantly, NanoSpot.ai enabled impartial test analysis, free of the subjectivity of individual investigators. Still, we believe that the quantification approach can be improved, in particular through generation of a continuous standard curve (as opposed to the discontinuous bins currently used). This could possibly be accomplished through generation of a regression curve based on existing bin-labeled data or, alternatively, based on de-novo, pairwise comparison of large numbers of spots with different levels of agglutination by human investigators to generate a more fine-grained agglutination ranking scale, followed by re-training of AI. It is likely that such more precise methods will improve overall quantification and, ultimately, allow for more accurate test interpretation, particularly for low-titer cases. As noted, some NanoSpot.ai tests were invalid due to image acquisition and respectively low AI confidence scores. While improvement of the image capture app will likely reduce focusing errors, an important area for improvement will be additional AI training. Specifically, by broadening the spectrum of agglutination samples, including those with imperfections, such as air bubbles or sample preparation issues, AI will be empowered to ignore such artifacts or, if significant, to invalidate the test upon detecting them. Importantly, as opposed to most other tests, the instant notification through NanoSpot.ai and its simple assay format endorses immediate test repetition, thus mitigating undue delays of diagnoses.

Three recent reports used agglutination assays for detection of SARS-CoV-2-specific AB, although in different formats. One focused on antigenic peptides from the Spike proteins, which were chemically linked to a RBCspecific antibody, and agglutination was assessed visually in column agglutination tests (CAT) 23 . Although only few patients were analyzed and sensitivity and specificity, respectively positive and negative agreement with standard tests remain to be evaluated, this format is scalable and can be performed with basic lab equipment. It is, however, neither quantitative nor particularly suitable for POC settings. Two other reports focused on 96 well plate readouts, where agglutination is reflected by morphological changes in blood settling 24 25 . Both reports relied on the Spike-RBD, similar to NanoSpot.ai. One of these reports used RBC-specific single-chain variable fragments (scFv), while the other one used the Glycophorin-A-specific nanobody, similar to NanoSpike. While the former paper was limited to proof-of-principle assays with three COVID-19 patient samples 25 , the latter report involved larger patient numbers, and direct comparison with an approved Spike-RBD CLIA (Siemens) suggested overall comparable test performance 24 In summary, data available so far indicate that NanoSpot.ai could represent a viable alternative to currently used POC tests, combining diagnostic specificity and sensitivity with distinct simplicity, speed, objectivity and, likely, low costs. Not least, given the possibility to exchange the antigen moiety, NanoSpot.ai may serve as a platform to implement further, SARS-CoV2-unrelated AB tests.

Codon-optimized DNA encoding expressed proteins was synthesized by commercial suppliers (ThermoFisher Scientific/ Invitrogen, Synbio, Biomatic) and cloned by standard molecular biology methods into the mammalian expression vector pcDNA3.1(+) (Thermo Fisher Scientific, Invitrogen). All coding sequences were confirmed by Sanger sequencing. To allow for efficient secretion in mammalian cells, the Glycophorin A-specific IH4 nanobody was modified by a F80Y mutation and insertion of a threonine C-terminal of G117 as described previously 26 .

The Spike-RBD (amino acids 328-533) was derived from SARS-CoV-2 isolate Wuhan-Hu-1 (UniProtKB -P0DTC2, SPIKE_SARS2). Full-length Nucleocapsid (AS1-419) was derived from SARS-CoV-2 isolate Wuhan-Hu-1 (UniProtKB -P0DTC9, NCAP_SARS2). The sequence of the Spike-RBD-recognizing nanobody H11-D4 was used as published and fused N-terminal of the human IgG-FC domain as found in Etanercept (16) .

All proteins were expressed in Expi293F cells (ThermoFisher Scientific) using the ExpiFectamine™ 293

Transfection Kit following the manufacturer's instructions (ThermoFisher Scientific). In brief, cells were cultured at 37°C and 8% CO2 in 25 ml of Expi293 expression medium (ThermoFisher Scientific) in 125 ml bottles on a 25 mm orbital shaker (120 rpm) until reaching a density of 4.5-5.5x10e6/ml. Cells were seeded at 3x10e6/ml in and Sypro Ruby staining (ThermoFisher Scientific).

Human de-identified blood and serum samples obtained by venipuncture were used in this study. instructions. This is a semi-quantitative high-throughput chemiluminescent immunoassay (CLIA) that detects

IgG to the S1 RBD region of SARS-CoV-2 Spike. According to the manufacturer, there is a direct relationship between the amount of SARS-CoV-2 antibody present in the patient sample and the amount of relative light units (RLU) detected by the system. A result of reactive or nonreactive is determined according to the Index Value established with the kit calibrators. A sample is considered reactive or positive for S1 RBD IgG when the Index is ≥1.00. The EUROIMMUN assay was performed manually according to the manufacturer's instructions using the Anti-SARS-CoV-2 IgG Enzyme Linked Immunosorbent Assay (EUROIMMUN US, Mountain Lakes, NJ). The assay format is a 96-well microtiter plate coated with SARS-CoV-2 recombinant S1 spike protein provided by the manufacturer (EUROIMMUN). Results are calculated as the ratio between the OD of the sample and the OD of the calibrator. This sample to calibrator ratio is interpreted as negative when the ratio is below 0.8, borderline if the ratio is between 0.8 and 1.1, and positive if the ratio is greater than or equal to 1.1.

All results were interpreted according to the manufacturer's cutoffs.

The S-Flow assay was performed as previously described with minor modifications 20 

An object detection network based on YOLOv3 with anchor boxes set to 400 pixels square was used to identify agglutinated and non-agglutinated blood spots 27 . Potential training labels were statistically divided into Training and Validation sets in an approximately 9:1 ratio for each class. Training labels were oversampled such that every class had an equal number of presentations to the model in training. The resulting set of training images was presented to the model in each epoch, and the validation images were used to measure training progress after each epoch. Training images were randomly flipped and rotated at 90 degree intervals, and image hue and saturation were randomly augmented by as much as 10 percent. The model was trained using stochastic gradient descent with backpropagation using a batch size of 12 and starting with a learning rate of 1e-4 which decreased over 7 epochs to 1e-5. Since training and validation images were selected from a common set of image captures, a holdout set composed of distinct image captures that were entirely withheld from the training process was used to test the final trained model for generalized performance. Model predictions consist of object bounding box location and size, object type (i.e., agglutinated blood spot, non-agglutinated blood spot), and confidence value in range, [0, 1]. An arbitrary minimum-confidence threshold of 0.2 was used to filter out spurious predictions. On the holdout set, this model produced one high-confidence spurious prediction. It was much larger than a valid blood spot in the NanoSpot.ai system and was ignored on that basis.

For quantitative AI analysis, a total of 2828 agglutination images were assigned visually (by agreement of three investigators) to 10 arbitrary bins according to the level of agglutination (Fig. 6a ) ranging from no agglutination at level 0 to maximum observed agglutination at level 9, separated into sets of 2326 training, 265 validation, and 237 holdout labels. Again, the holdout set was composed of an exclusive set of image captures that were not presented to the model during the training process. The training and validation data sets were used to train a second model using the same architecture and training procedure as the first, with the output being a discrete agglutination level for each spot rather than positive or negative identification. Through testing on the expanded holdout set, it was determined that the quantitative model would benefit from a spurious object confidence threshold of 0.5, in contrast to the original arbitrary threshold of 0.2. In addition to filtering spurious predictions by confidence, the standardized layout and geometry of the NanoSpot.ai card enables valid blood spot predictions to be constrained to appropriate sizes and locations, further enhancing the robustness of the analysis process.

We developed an iOS mobile application using the camera and networking capabilities of an iPhone to capture the NanoSpot.ai card images and upload them to the Techcyte AI platform for analysis. Two QR codes, placed on the opposite sides of the card, are used to identify the manufacturing data about the card and provide a unique ID for each test card. The mobile app also uses the QR codes to ensure the image is captured when the orientation and distance to the card are correct and the image is in focus. To ensure that the picture is taken at the correct time, the app scans the QR codes and initiates a countdown timer that notifies the technician when the picture should be taken to produce a valid result. For the clinical study, the mobile app was used in conjunction with an LED illumination box (Photo Studio Box, Depthlan) to maximize the consistency of the test card image captures. The test results were then interpreted on the Techcyte web application. In the future, the results of the test will be sent directly back to the mobile app for presentation at the point of care.

All research involving human participants was performed in accordance with relevant guidelines/regulations.

Samples were collected under informed consent from healthy donors and individuals with SARS-CoV-2 infection.

The study was approved by the University of Utah Institutional Review Board under the active protocols IRB# 131664 and IRB# 00007740.

Antibody Tests in Detecting SARS-CoV-2 Infection: A Meta-Analysis. Diagnostics (Basel)

Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis

Clinical and laboratory evaluation of SARS-CoV-2 lateral flow assays for use in a national COVID-19 seroprevalence survey

Clinical Evaluation of a COVID-19 Antibody Lateral Flow Assay using Point of Care Samples. medRxiv

Autologous red cell agglutination assay for HIV-1 antibodies: simplified test with whole blood

Whole-blood agglutination assay for on-site detection of human immunodeficiency virus infection

V(H)H (nanobody) directed against human glycophorin A: a tool for autologous red cell agglutination assays

Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine

Antibody signature induced by SARS-CoV-2 spike protein immunogens in rabbits

SARS-CoV-2 SPIKE PROTEIN: an optimal immunological target for vaccines

Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome

The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients

Distinct antibody responses to SARS-CoV-2 in children and adults across the COVID-19 clinical spectrum

Sensitivity in Detection of Antibodies to Nucleocapsid and Spike Proteins of Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Coronavirus Disease

Analysis of the SARS-CoV-2 spike protein glycan shield reveals implications for immune recognition

Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2

Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera

mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants. bioRxiv

The N501Y mutation in SARS-CoV-2 spike leads to morbidity in obese and aged mice and is neutralized by convalescent and post-vaccination human sera. medRxiv

A comparison of four serological assays for detecting anti-SARS-CoV-2 antibodies in human serum samples from different populations

Lateral flow (immuno)assay: its strengths, weaknesses, opportunities and threats. A literature survey

Using artificial intelligence to improve COVID-19 rapid diagnostic test result interpretation

Rapid Gel Card Agglutination Assays for Serological Analysis Following SARS-CoV-2 Infection in Humans

A haemagglutination test for rapid detection of antibodies to SARS-CoV-2

A rapid, point-of-care red blood cell agglutination assay detecting antibodies against SARS-CoV-2

Rational Design of a Bifunctional AND-Gate Ligand To Modulate Cell-Cell Interactions

An incremental improvement

We thank Jungmin Lee for helpful suggestions related to modification of the IH4 nanobody. This work was supported by a seed grant from the University of Utah Vice President for Research and the Immunology, 

VR and HH serve as inventors on a patent application by the University of Utah (related to the constructs